BioNTech SE (BioNTech SE) FCF Margin % : 44.67% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioNTech SE's Free Cash Flow for the three months ended in Dec. 2023 was $721 Mil. BioNTech SE's Revenue for the three months ended in Dec. 2023 was $1,613 Mil. Therefore, BioNTech SE's FCF Margin % for the quarter that ended in Dec. 2023 was 44.67%.

As of today, BioNTech SE's current FCF Yield % is 24.07%.

The historical rank and industry rank for BioNTech SE's FCF Margin % or its related term are showing as below:

BNTX' s FCF Margin % Range Over the Past 10 Years
Min: -248.25 Med: -20.51 Max: 122.86
Current: 122.86

During the past 8 years, the highest FCF Margin % of BioNTech SE was 122.86%. The lowest was -248.25%. And the median was -20.51%.

BNTX's FCF Margin % is ranked better than
98.26% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs BNTX: 122.86

BioNTech SE FCF Margin % Historical Data

The historical data trend for BioNTech SE's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE FCF Margin % Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-248.25

-20.51

3.88

76.34

122.18

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															16.00	-57.34	2,431.37	73.72	44.67

Competitive Comparison of BioNTech SE's FCF Margin %

For the Biotechnology subindustry, BioNTech SE's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioNTech SE's FCF Margin % falls into.

BioNTech SE FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioNTech SE's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	5088.222	/	4164.667
	=	122.18 %

BioNTech SE's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	720.502	/	1612.868
	=	44.67 %

BioNTech SE FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioNTech SE's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.